PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$254.00

07 Mar
2025

-11.050

OPEN

$264.00

-4.17%

HIGH

$266.37

326,756

LOW

$253.30

TARGET
$242.25 -4.6% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 79.3 113.5 xxx
DPS (cps) xxx 40.0 55.6 xxx
EPS Growth xxx 36.5% 43.2% xxx
DPS Growth xxx 33.3% 39.0% xxx
PE Ratio xxx N/A 223.7 xxx
Dividend Yield xxx N/A 0.2% xxx
Div Pay Ratio(%) xxx 50.5% 49.0% xxx

Dividend yield today if purchased 3 years ago: 0.87%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.16

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx79.3
DPS All xxxxxxxxxxxxxxx40.0
Sales/Revenue xxxxxxxxxxxxxxx161.5 M
Book Value Per Share xxxxxxxxxxxxxxx179.8
Net Operating Cash Flow xxxxxxxxxxxxxxx86.8 M
Net Profit Margin xxxxxxxxxxxxxxx51.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx50.72 %
Return on Invested Capital xxxxxxxxxxxxxxx50.30 %
Return on Assets xxxxxxxxxxxxxxx36.03 %
Return on Equity xxxxxxxxxxxxxxx50.72 %
Return on Total Capital xxxxxxxxxxxxxxx67.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx79.69

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

14/02/2025

5

Sell

$165.00

-35.04%

Citi highlights Pro Medicus reported robust revenue growth of 31%, while earnings before interest and tax (EBIT) advanced by 45%, coming in below consensus by -2%.

Net profit after tax was 3% better than forecast due to increased interest income from a cash balance of $181m. EBIT margins lifted 691bps on the previous corresponding period to 72%, the broker details.

Notably, the company signed its first cardiology customer, with a total addressable market around 20% of radiology, the analyst states. Citi's US market share estimate increased to 9% from 7% in August.

Citi lifts EPS forecasts by 4% in FY25/FY26 and anticipates a compound average EPS growth rate of around 31% per annum from FY24 to FY30, noting that the stock's valuation implies higher growth.

Sell rated with a $165 target price, up from $150.

FORECAST
Citi forecasts a full year FY25 dividend of 55.60 cents and EPS of 110.80 cents.
Citi forecasts a full year FY26 dividend of 76.80 cents and EPS of 153.60 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

17/02/2025

3

Downgrade to Market Weight from Overweight

$297.00

16.93%

Pro Medicus' 1H25 topline revenue of $97M missed Wilsons' estimate by -7% but the broker admits it was a case of its forecast being too high. Overall, directionally the result met the broker's expectations.

The broker lowered FY25 revenue estimates on account of the 1H miss while leaving 2H forecasts unchanged. FY26 forecast was lifted by 1.2% owing mainly to new contracts.

Target price rises to $297 from $275 but rating lowered to Market Weight from Overweight.

FORECAST
Wilsons forecasts a full year FY25 dividend of 53.70 cents and EPS of 107.70 cents.
Wilsons forecasts a full year FY26 dividend of 67.80 cents and EPS of 137.20 cents.

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Next Week At A Glance – 10-14 Mar 2025

Mar 07 2025 - Weekly Reports
2
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports
3
Rudi’s View: To Sell Or Not To Sell

Mar 06 2025 - Rudi's View
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 21-02-25

Feb 21 2025 - Weekly Reports
5
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps